Clinical trial · Interventional
Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials
A Screening Protocol to Support Preliminary Eligibility for Clinical Trials Evaluating Safety and Efficacy of Adoptive Cell Therapies in Participants With Solid Tumors and Hematologic Malignancies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Trial terminated due to feasibility reasons
Summary
Brief summary (as posted)
This screening study is intended to determine preliminary eligibility of participants who may be potential candidates for GlaxoSmithKline's Adoptive T-cell therapy studies by screening for appropriate biomarkers. No treatment intervention will occur as part of this screening study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Screening Platform | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Participants with solid tumors and hematological malignancies
- description
- Participants with solid tumors and hematological malignancies will be included. No study treatment will be administered in this study.
- interventionNames
- Other: Screening Platform
Primary outcomes (1)
- measure
- Number of Participants With Human Leukocyte Antigen (HLA) A Genotypes Status
- timeFrame
- Up to 2 weeks
- description
- Blood samples were collected for HLA compatibility testing. Number of participants with eligible human leukocyte antigen (HLA) A genotypes status are presented. Data has been reported for following categories: One HLA Allele Positive, Two HLA Allele Positive, Negative and Ambiguous.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 10 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of locally advanced high-risk eligible tumor types . * Participant must be greater than or equal to (\>=)18 years of age (or \>=10 years of age with synovial sarcoma or myxoid/round cell liposarcoma \[MRCLS\]) * Participants with life expectancy of greater than 6 months * Performance status: Eastern Cooperative Oncology Group 0-1. Exclusion Criteria: * Any prior treatment with oncology cell and/or gene therapy (unless agreed in advance with Sponsor) * Prior malignancy not in complete remission. * Clinically significant systemic illness * Serious active infections or significant cardiac, pulmonary, hepatic or other organ dysfunction, * Prior or active demyelinating disease * Previous New-York Esophageal Antigen-1 (NY-ESO-1)-specific T cells, NY-ESO-1 vaccine, or NY-ESO-1 targeting antibody. * Previous allogeneic hematopoietic stem cell transplant within the last 5 years or solid organ transplant.
References
Publications (0)
Data not yet available